Developmental Research Program

发展研究计划

基本信息

批准号：
8933154
负责人：
John Munn Kirkwood
金额：
$ 2.32万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-26 至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8933154
关键词：
Advocate Antibodies Applications Grants Area Award BRAF gene Basic Science Biostatistics Core Chicago Clinical Clinical Research Collaborations Cutaneous Melanoma Data Development Developmental Therapeutics Program Ensure Funding Grant Immunologist Immunosuppression Immunotherapy Informatics Institutes Institution Leadership Major Histocompatibility Complex Medical Oncologist Mentors Molecular Patients Peer Review Pilot Projects Preparation Principal Investigator Process Program Research Project Grants Research Research Personnel Research Support Resistance Resources Rewards Seeds Services Skin Cancer Specialist Surgical Oncologist System T-Lymphocyte Translational Research Translations Treatment outcome Universities Vaccines Virginia base cancer diagnosis cancer research center director chemotherapy high reward high risk improved inhibitor/antagonist innovation interest meetings melanoma novel programs success tumor tumor microenvironment

项目摘要

The MSCP SPORE Developmental Research Program (DRP) provides seed funding to explore promising novel research in melanoma and other skin cancers, particularly by investigators not currently engaged in research in this area. The DRP solicits proposals twice a year and to use a peer-reviewed scoring system to prioritize proposals for funding. The DRP Directors and Executive Committee, Internal Advisory Board and External Advisory Board participate in the review process, together with the Patient Advocates and any additional experts who may be called upon if special reviewer expertise is necessary. During the past grant period, the MSCP SPORE funded 9 DRP projects in basic, translational, and clinical research. The DRP Directors track the progress of the successful applications and assign mentors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A, Biospecimen Core B, Biostatistics Core C, and Informatics Core D) and that they are effectively integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of funding to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether DRP projects are found to merit promotion to full SPORE projects; in the past funding period, productive and innovative research funded by DRP awards to Drs. Hassane Zarour and Soldano Ferrone has been promoted to a full project. Project 3, in this renewal application. Awardees are also advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE Core resources to aid in this endeavor. DRP-supported research has led to 3 NCI awards (R01CA154728, R01CA157467, R01CA169118) and a pilot award funded by the University of Pittsburgh Clinical Translational Science Institute Basic to Clinical Collaborative Research Pilot Program. There are also several grant applications submitted or planned based on DRP results from the previous grant period, including an R21 and two additional R01 applications.

MSCP SPORE 发展研究计划 (DRP) 提供种子资金，以探索黑色素瘤和其他皮肤癌方面有前途的新颖研究，特别是目前尚未从事该领域研究的研究人员。 DRP 每年两次征求提案，并使用同行评审的评分系统来确定资助提案的优先顺序。 DRP 董事和执行委员会、内部顾问委员会和外部顾问委员会以及患者权益倡导者和在需要特殊审核员专业知识时可能需要的任何其他专家一起参与审核过程。在过去的资助期内，MSCP SPORE 资助了 9 个 DRP 项目，涉及基础、转化和临床研究。发展计划董事跟踪成功申请的进度，并向受资助的研究人员指派导师，以确保他们从 MSCP SPORE 核心（管理核心 A、生物样本核心 B、生物统计核心 C 和信息学核心 D）获得任何所需的服务，并且他们有效地集成到 SPORE 程序中。获得一年资助后，获奖者向 SPORE 研究人员展示他们的研究成果，才有资格获得第二年的支持。翻译以及影响力和创新方面的进展将决定 DRP 项目是否值得升级为完整的 SPORE 项目；在过去的资助期内，DRP 资助的富有成效和创新的研究授予了博士。哈桑·扎鲁尔和 Soldano Ferrone 已升级为完整项目。本续签申请中的项目 3。获奖者还可以酌情建议准备 SPORE 机制之外的资助拨款申请，并获得 SPORE 核心资源来协助这一努力。 DRP 支持的研究已获得 3 个 NCI 奖项（R01CA154728、R01CA157467、R01CA169118）以及由匹兹堡大学临床转化科学研究所基础到临床合作研究试点计划资助的试点奖项。还有一些根据上一个资助期的 DRP 结果提交或计划的资助申请，包括 R21 和另外两个 R01 申请。